# Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

> **NCT07502001** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Acetaminophen
- **DRUG:** Metformin
- **DRUG:** Warfarin
- **DRUG:** Atorvastatin
- **DRUG:** Digoxin
- **DRUG:** HDM1005 injection

## Key facts

- **NCT ID:** NCT07502001
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-08
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-06-02
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502001, "Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07502001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*